Teachers Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.4% in the third quarter, Holdings Channel reports. The fund owned 4,964,053 shares of the company’s stock after purchasing an additional 382,825 shares during the period. Johnson & Johnson accounts for about 0.8% of Teachers Advisors LLC’s investment portfolio, making the stock its 10th largest holding. Teachers Advisors LLC’s holdings in Johnson & Johnson were worth $685,883,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of JNJ. Fundsmith Equity Fund L.P. bought a new stake in Johnson & Johnson in the 2nd quarter worth approximately $552,762,000. Peoples Financial Services CORP. lifted its position in Johnson & Johnson by 20.4% in the 3rd quarter. Peoples Financial Services CORP. now owns 30,668 shares of the company’s stock worth $4,237,000 after buying an additional 5,190 shares during the last quarter. Sather Financial Group Inc lifted its position in Johnson & Johnson by 3.7% in the 2nd quarter. Sather Financial Group Inc now owns 11,051 shares of the company’s stock worth $1,341,000 after buying an additional 399 shares during the last quarter. QUANTRES ASSET MANAGEMENT Ltd bought a new stake in Johnson & Johnson in the 3rd quarter worth approximately $829,000. Finally, Foundation Resource Management Inc. bought a new stake in Johnson & Johnson in the 3rd quarter worth approximately $208,000. Hedge funds and other institutional investors own 66.56% of the company’s stock.
Johnson & Johnson stock traded down $0.55 during trading hours on Friday, reaching $137.47. The company had a trading volume of 63,757 shares, compared to its average volume of 7,208,329. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20. The stock has a market capitalization of $373.41 billion, a P/E ratio of 16.78, a price-to-earnings-growth ratio of 2.13 and a beta of 0.68. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 EPS for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.02. The business had revenue of $20.39 billion for the quarter, compared to analysts’ expectations of $20.27 billion. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The business’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.74 EPS. Sell-side analysts expect that Johnson & Johnson will post 8.57 earnings per share for the current fiscal year.
Johnson & Johnson declared that its board has initiated a stock buyback plan on Monday, December 17th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 1.5% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 12th. Stockholders of record on Tuesday, February 26th were paid a dividend of $0.90 per share. The ex-dividend date of this dividend was Monday, February 25th. This represents a $3.60 annualized dividend and a dividend yield of 2.62%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 44.01%.
A number of research firms recently weighed in on JNJ. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 4th. Barclays restated an “equal weight” rating and issued a $135.00 target price (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. ValuEngine upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. Citigroup boosted their target price on Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a research report on Monday, February 25th. Finally, Morgan Stanley decreased their price target on Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $142.81.
COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Stake Increased by Teachers Advisors LLC” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2019/03/15/johnson-johnson-jnj-stake-increased-by-teachers-advisors-llc.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Leveraged Buyout (LBO)
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.